Blinatumomab: Phase I start

By year end, Micromet will begin a U.S. Phase I trial of IV blinatumomab. AstraZeneca’s MedImmune Inc. subsidiary licensed North American rights to MT103 from Micromet in 2004 (see BioCentury, June 15...